Chretien, M., Hebraud, B., Cances-Lauwers, V., Hulin, C., Marit, G., Leleu, X., . . . Corre, J. (2014). Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: The IFM experience on 2316 patients. Ferrata Storti Foundation.
Styl ChicagoChretien, Marie-Lorraine, et al. Age Is a Prognostic Factor Even Among Patients With Multiple Myeloma Younger Than 66 Years Treated With High-dose Melphalan: The IFM Experience On 2316 Patients. Ferrata Storti Foundation, 2014.
Citace podle MLAChretien, Marie-Lorraine, et al. Age Is a Prognostic Factor Even Among Patients With Multiple Myeloma Younger Than 66 Years Treated With High-dose Melphalan: The IFM Experience On 2316 Patients. Ferrata Storti Foundation, 2014.